Meeting on big mutations addresses big questions in human genetics by Conrad, Donald F
Introduction
Low-cost  technologies  for  variation  discovery  that  can 
screen entire genomes (such as oligonucleotide arrays) have 
been  available  to  researchers  studying  copy  number 
variations (CNVs) for several years. These technologies allow 
them to zero in on extremely rare, large-effect mutations 
that  could  not  be  found  by  endeavors  based  on  single-
nucleotide polymorphisms (SNPs), such as the International 
HapMap Project (http://hapmap.ncbi.nlm.nih.gov/) and the 
hundreds of genome-wide association studies (GWASs) 
that it enabled. As the high-profile questions in human 
genetics  have  turned  from  the  biology  of  common 
variation  to  the  properties  of  rare  mutations  and  the 
process of mutation itself, those scientists who initially 
set  out  to  study  CNV  itself  now  find  themselves  in  a 
position  to  address  some  of  the  biggest  current 
questions.  This  was  manifest  in  January’s  Keystone 
Symposium on structural variation, which featured talks 
dissecting  the  extent  of  rare  variation  and  somatic 
mosaicism and their impact on health, presen  tations on 
measurement  and  analysis  of  mutation  and  mutation 
rates,  and  talks  about  phenotypes  of  in  vivo  cellular 
models derived using induced pluripotent stem (iPS) cell 
technology. Here, I cover some of the highlights, ranging 
from  well  established  areas  (see  section  ‘Common 
CNVs’),  present-day  darlings  (‘Rare  CNVs’),  and  the 
impressive  foundations  that  are  being  put  in  place  to 
translate  genetic  research  into  clinical  tools  (‘Towards 
genomic medicine’).
Common CNVs
The  mapping  and  characterization  of  common  germline 
structural variation is quickly becoming a mature field. Ryan 
Mills (Harvard Medical School and Brigham and Women’s 
Hospital, Boston, USA) discussed the progress that the 1000 
Genomes Project (http://www.1000genomes.org) has made 
towards mapping all structural variations (SVs) with over 
1% frequency to base-pair level resolution in populations 
from three continents. In the pilot phase of the project, 
over 28,000 CNVs have been discovered, ranging in size 
from 50 bp to over 500 kb. These numbers are consistent 
with  previous  analyses  of  the  common  CNV  universe, 
which  estimate  that  there  are  4,000  to  5,000  common 
deletions over 450 bp in size in European populations. 
Importantly,  the  1000  Genomes  Project  data  set 
contributes several forms of SV mutation that had been 
poorly documented until now - mobile elements, such as 
long  interspersed  nuclear  elements  (LINEs)  and  Alus, 
and  insertions  of  sequence  not  seen  in  the  human 
reference genome.
Although  many  people  expected  that,  compared  with 
SNPs,  common  CNVs  would  contribute  dispropor  tion-
ately to the variation in risk for common diseases, the past 
3  years  of  CNV  GWASs  has  provided  no  evidence  to 
support  this  hypothesis,  as  summarized  by  Matthew 
Hurles (Wellcome Trust Sanger Institute, Hinxton, UK). 
One potential explanation for this counterintuitive find  ing 
is that the traits studied so far have been prioritized for 
their  medical  interest,  and  common  CNVs,  whose 
locations are biased toward specific genes and genomic 
regions, are likely to have an impact on more superficial 
traits, such as olfaction, digestion, taste, and pigmentation.
Rare CNVs
The  same  array  technologies  that  have  enabled  whole-
genome  mapping  of  common  variants  have  also  been 
successful  in  helping  researchers  identify  many  pre-
viously unknown genomic disorders and to characterize 
CNV mutation processes. In the keynote address, James 
Lupski  (Baylor  College  of  Medicine,  Houston,  USA) 
reviewed  his  contributions  to  the  field,  from  the 
description of non-allelic homologous recombination as 
the mutation process forming the recurrent aneuploidies 
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introduction of a mutation model called microhomology-
mediated break-induced replication that can form CNVs 
of arbitrary complexity. He then announced the exciting 
discovery  of  a  new,  as  yet  unnamed  CNV  mutation 
process, which produces a nested duplication-triplication-
duplication structure.
Evan Eichler (University of Washington, Seattle, USA) 
presented a summary of the 17 rare, recurrent micro  dupli-
cations  and  microdeletions  that  his  laboratory  has  dis-
covered to be associated with intellectual disability, autism, 
and epilepsy; all this from an explosion of work in just the 
past 5 years. Rare variant analyses also featured promi-
nently in a talk on autism by Dalila Pinto (Hospital for Sick 
Children,  Toronto,  Canada),  who  reported  an  increased 
rate of de novo CNVs in children with autism compared 
with controls, and much larger de novo CNVs in children 
from  simplex  families  (with  only  one  affected  member) 
than from multiplex families (with more than one).
The final frontier in rare variant analysis, the rarest of 
the rare, is the somatic mutations that segregate among 
different cells of the same individual. SNP arrays are an 
important  new  tool  for  the  analysis  of  mosaicism: 
because of their sensitive quantification of allele-specific 
copy number, it is now possible to reliably detect mosaic 
aneuploidies and uniparental disomies with frequencies 
down  to  5%  or  less  in  a  population  of  cells,  allowing 
researchers to describe both the normal distribution of 
mosaicism in healthy individuals and previously cryptic 
pathologies. Nancy Spinner (Children’s Hospital of Phila-
delphia, USA) reviewed results from 459 patients with 
cytogenomic  abnormalities  visible  on  Illumina  Quad2 
arrays; 60 (13%) of these cases were mosaic. In his talk on 
somatic  mutation  and  aging,  Jan  Dumanski  (Uppsala 
University,  Uppsala,  Sweden)  described  an  increase  in 
the  number  somatic  mutations  in  apparently  healthy 
monozygotic  twins  over  60  years  old  compared  with 
younger twin pairs, and estimated that 3 to 4% of the 
population over 60 years old are mosaic for a large CNV 
that is detectable with current technology.
Towards genomic medicine
Two challenges for genomic medicine are in vivo func-
tional characterization of mutations in human cells and 
quantification of the probability that a known or novel 
variant is causally related to disease. Several talks at the 
meeting addressed these challenges.
Perhaps  the  most  exciting  new  development  at  this 
meeting were the first reports from groups that are starting 
to investigate the functional impact of structural variation 
in human iPS cells, in vivo systems that can be used to 
directly model disease states. Kristen Brennand (The Salk 
Institute, La Jolla, USA) presented impressive results from 
her studies of neurons derived from iPS cells of individuals 
with  apparently  familial  cases  of  schizo  phrenia  and 
controls. Compared with controls, cells from people with 
schizophrenia  demonstrated  lower  neural  connectivity, 
reduced neurite outgrowth, gene expression changes, and 
impaired synaptic transport, the latter of which improved 
after  treatment  with  the  antipsychotic  drug  loxapine. 
Jonathan Sebat (University of California, San Diego, USA) 
reported an exciting new association between duplication 
of  the  vasoactive  intestinal  peptide  receptor  2  (VIPR2) 
gene and schizophrenia; experiments are under way to test 
the impact of VIPR2 antagonists in schizophrenia-derived 
iPS  cell  systems.  Ira  Hall  (University  of  Virginia, 
Charlottesville,  USA)  presented  for  the  first  time 
experiments  investigating  the  impact  of  inducible 
reprogramming on genome stability. There is a concern 
that the reprogramming factors used by iPS cell technology 
may accelerate the rate of somatic mutation, adding noise 
to assays of single mutations; fortunately, Ira’s preliminary 
results suggest that this effect is likely to be modest.
The identification of causal mutations in severe cases of 
pediatric disease is a rapidly changing area of medical 
inference. As the size spectrum of unresolved disease-
causing mutations gets smaller, the overlap with benign 
variation  increases,  and  the  calls  for  ‘evidence-based’ 
assess  ment  of  causality  are  mounting.  As  a  result,  the 
leaders  in  medical  genetics  across  the  world  have  em-
braced statistical thinking, as reflected in massive array 
datasets described by Lisa Schaffer (Signature Genomic 
Laboratories,  Spokane,  USA),  presenting  the  Signature 
Genomics  database,  and  David  Ledbetter  (Geisinger 
Health  System,  Danville,  USA),  presenting  analysis  of 
CNV  data  from  the  International  Standards  for  Cyto-
genomic Arrays (ISCA) Consortium. With sample sizes 
over 45,000 and over 15,000, respectively, these medical 
genetics projects have moved into a scale previously only 
obtained  by  the  largest  GWAS  meta-analyses.  Both 
speakers  estimate  that  causal  mutations  have  been 
identified for 15 to 25% of the cases in each database and 
highlighted cases in which previously unknown disease 
mutations were identified by rigorous statistical analysis. 
Although  medical  genetics  will  no  doubt  continue  to 
identify new causal variants with the same paradigm of 
case-control association used by GWASs, it is important 
to set our sights higher and develop new methods for 
assessing  causality  for  mutations  that  have  never  been 
seen before. Conceptually this might be done by finding 
features  generally  enriched  in  known  disease-causing 
mutations and then assessing the evidence, by analogy 
with  con  firmed  disease  variants,  that  an  unclassified 
variant is causal.
The vanguard of human genetics
It is clear that leaders in the CNV field are now addressing 
questions  of  broad  interest  across  human  genetics, 
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and embraced statistical thinking. Investigators of CNV 
have  broadened  their  experimental  toolkit  and  talks 
routinely  navigated  data  from  fluorescence  in  situ 
hybridi  zation experiments, SNP arrays, array compara-
tive genomic hybridization, and next generation sequen  c-
ing.  As  next-generation  sequencing  matures,  and  the 
inte  grated  analysis  of  all  human  variation  becomes 
routine, I predict that the scientific stereotype currently 
recognized as ‘the CNV guy’ will start to be referred to as 
‘the human geneticist’.
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